Gaps in scientific knowledge for the post eradication world

Biologicals

Volumn 34, Issue 2, 2006, Pages 167-170

  Minor, Philip ^a  

^a NATIONAL INSTITUTE FOR BIOLOGICAL STANDARDS AND CONTROL   (United Kingdom)

Author keywords

Long term excretors; Stopping virus excretion; Vaccine production strains; Vaccine safety

Indexed keywords

POLIOMYELITIS VACCINE;

ARTICLE; DRUG EFFICACY; DRUG MANUFACTURE; DRUG SAFETY; DRUG USE; POLIOMYELITIS VIRUS; PRIORITY JOURNAL; VIRUS EXCRETION;

HUMANS; POLIOMYELITIS; POLIOVIRUS; POLIOVIRUS VACCINE, INACTIVATED; SPECIES SPECIFICITY;

POLIOVIRUS;

EID: 33646781258     PISSN: 10451056     EISSN: 10958320     Source Type: Journal    
DOI: 10.1016/j.biologicals.2006.02.006     Document Type: Article

References (24)

1. WHO consultative group. Evidence on the safety and efficacy of live poliomyelitis vaccines currently in use, with special reference to type 3 poliovirus. Bull World Health Organ 40 (1969) 925-945
2. Minor P.D., Kew O., and Schild G.C. Poliomyelitis-epidemiology, molecular biology and immunology. Nature 299 5879 (1982) 109-110
3. Minor P.D., Schild G.C., Ferguson M., Mackay A., Magrath D.I., John A., et al. Genetic and antigenic variation in type 3 polioviruses: characterization of strains by monoclonal antibodies and T1 oligonucleotide mapping. J Gen Virol 61 Pt 2 (1982) 167-176
4. Ferguson M., Magrath D.I., Minor P.D., and Schild G.C. WHO collaborative study on the use of monoclonal antibodies for the intratypic differentiation of poliovirus strains. Bull World Health Organ 64 2 (1986) 239-246
5. van Wezel A.L., van Steenis G., van der Marel P., and Osterhaus A.D.M.E. Inactivated poliovirus vaccine: current production methods and new developments. Rev Infect Dis 6 Suppl. 2 (1984) 335-340
6. Nathanson N., and Langmuir A.D. The Cutter incident: poliomyelitis following formaldehyde inactivated poliovirus vaccination in the United States during the spring of 1955. Am J Hyg 78 (1963) 16-81
7. Sabin A.B. Pathogenesis of poliomyelitis: reappraisal in the light of new data. Science 123 (1956) 1151-1157
8. Contreras G., Dimock K., Furesz J., Gardell G., Hazlett D., Karpinski K., et al. Genetic characterisation of Sabin types 1 and 3 poliovaccine virus following serial passage in the human intestinal tract. Biologicals 20 (1992) 15-26
9. Minor P.D. The molecular biology of poliovaccines. J Gen Virol 73 (1992) 3065-3077
10. Minor P.D., John A., Ferguson M., and Icenogle J.P. Antigenic and molecular evolution of the vaccine strain of type 3 poliovirus during the period of excretion by a primary vaccine. J Gen Virol 67 (1986) 693-706
11. Fine PE, Carneiro IA. Transmissibility and persistence of oral poliovaccine viruses: implications for the global poliomyelitis eradication initiative. Am J Epidemiol 1999;150:1001-21.
12. Doi Y., Abe S., Yamamoto H., Horie H., Ohyama H., Satoh K., et al. Progress with inactivated poliovirus vaccines derived from the Sabin strains. Dev Biol (Basel) 105 (2001) 163-170 Karger
13. Dragunsky E.M., Ivanov A.P., Wells V.R., Ivshina A.V., Rezapkin G.V., Abe S., et al. Evaluation of immunogenicity and protective properties of inactivated poliovirus vaccines: a new surrogate method for predicting vaccine efficacy. J Inf Dis 190 (2004) 1404-1412
14. Ferguson M., Wood D.J., and Minor P.D. Antigenic structure of poliovirus in inactivated vaccines. J GenVirol 74 Pt 4 (1993) 685-690
15. Martin J., Crossland G., Wood D.J., and Minor P.D. Characterization of formaldehyde-inactivated poliovirus preparations made from live-attenuated strains. J Gen Virol 84 Pt 7 (2003) 1781-1788
16. Nkowane B.U., Wassilak S.G., and Orenstein W.A. Vaccine associated paralytic poliomyelitis in the United States: 1973 through 1984. JAMA 257 (1987) 1335-1340
17. Minor P.D. Immunization of pregnant women could protect babies from vaccine associated poliomyelitis. Vaccine 15 16 (1997) 1709
18. Minor P.D. Characteristics of poliovirus strains from long-term excretors with primary immunodeficiencies. Dev Biol (Basel) 105 (2001) 75-80 Karger
19. Misbah S.A., Lawrence P.A., Kurtz J.B., and Chapel H.M. Prolonged faecal excretion of poliovirus in a nurse wih common variable hypogammaglobulinaemia. Post grad Med J 67 (1991) 301-303
20. Savilahti E., Klemola T., Carlsson B., Mellander L., Stenvik M., and Hovi T. Inadequacy of mucosal IgM anti-bodies in selective IgA deficiency: excretion of attenuated polioviruses is prolonged. J Clin Immunol 8 (1999) 89-94
21. Minor P.D., Dunn G., Ramsay M.E., and Brown D. Effect of different immunisation schedules on the excretion and reversion of oral poliovaccine strains. J Med Virol 75 1 (2005) 153-160
22. MacLennan C., Dunn G., Huissoon A.P., Kumararatne D.S., Martin J., O'Leary P., et al. Failure to clear persistent vaccine-derived neurovirulent poliovirus infection in an immunodeficient man. Lancet 363 9420 (May 8, 2004) 1509-1513
23. Pevear D.C., Tull T.M., Seipel M.E., and Groarke J.E. Activity of pleconaril against enteroviruses. Antimicrob Agents Chemother 43 (1999) 2109-2115
24. MacCallum F.O. Hypogammaglobulinaemia in the United Kingdom, VII. The role of humoral antibodies in protection against and recovery from bacterial and viral infections in hypogammaglobulinaemia. Spec Rep Ser Med Res Counc 310 (1971) 72-85